SG11201911543UA - Synthesis of substantially diastereomerically pure phosphate protides - Google Patents

Synthesis of substantially diastereomerically pure phosphate protides

Info

Publication number
SG11201911543UA
SG11201911543UA SG11201911543UA SG11201911543UA SG11201911543UA SG 11201911543U A SG11201911543U A SG 11201911543UA SG 11201911543U A SG11201911543U A SG 11201911543UA SG 11201911543U A SG11201911543U A SG 11201911543UA SG 11201911543U A SG11201911543U A SG 11201911543UA
Authority
SG
Singapore
Prior art keywords
protides
synthesis
diastereomerically pure
substantially diastereomerically
pure phosphate
Prior art date
Application number
SG11201911543UA
Other languages
English (en)
Inventor
Hugh Griffith
Gordon Kennovin
Venkata Lakshmi Narasimha Rao Dammalapati
Mani Bushan Kotala
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of SG11201911543UA publication Critical patent/SG11201911543UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201911543UA 2017-06-14 2018-06-14 Synthesis of substantially diastereomerically pure phosphate protides SG11201911543UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709471.5A GB201709471D0 (en) 2017-06-14 2017-06-14 Diastereoselective synthesis of hosphate derivatives
PCT/GB2018/051638 WO2018229493A2 (en) 2017-06-14 2018-06-14 Synthesis of phosphate derivatives

Publications (1)

Publication Number Publication Date
SG11201911543UA true SG11201911543UA (en) 2020-01-30

Family

ID=59358400

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911543UA SG11201911543UA (en) 2017-06-14 2018-06-14 Synthesis of substantially diastereomerically pure phosphate protides

Country Status (18)

Country Link
US (4) US11414452B2 (enExample)
EP (2) EP3638684A2 (enExample)
JP (4) JP7248209B2 (enExample)
KR (2) KR20240127483A (enExample)
CN (3) CN110753697B (enExample)
AU (3) AU2018284131B2 (enExample)
BR (1) BR112019026747A2 (enExample)
CA (2) CA3064177A1 (enExample)
CL (1) CL2019003632A1 (enExample)
EA (1) EA201992873A1 (enExample)
GB (1) GB201709471D0 (enExample)
IL (3) IL271159B2 (enExample)
MA (1) MA49379A (enExample)
MX (3) MX391332B (enExample)
PH (1) PH12019502825A1 (enExample)
SA (1) SA519410795B1 (enExample)
SG (1) SG11201911543UA (enExample)
WO (2) WO2018229493A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
BR112016025787B1 (pt) 2014-06-25 2022-12-13 NuCana plc Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
JP6889180B2 (ja) 2015-12-11 2021-06-18 ニューカナ パブリック リミテッド カンパニー ホスフェート誘導体及びゲムシタビンプロドラッグnuc−1031のジアステレオ選択性合成
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN112409421A (zh) * 2020-12-01 2021-02-26 上海兆维科技发展有限公司 一种3’-磷酸酯核苷的制备方法
CA3252465A1 (en) 2022-05-12 2023-11-16 NuCana plc CANCER TREATMENT
EP4630433A1 (en) 2022-12-07 2025-10-15 NuCana plc Synthesis of nucleoside derivative nuc-3373

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279248C (enExample)
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4668777A (en) * 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7951789B2 (en) * 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090206007A1 (en) 2008-02-20 2009-08-20 Air Products And Chemicals, Inc. Process and apparatus for upgrading coal using supercritical water
WO2010081082A2 (en) 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
WO2010108140A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
SI2609923T1 (sl) 2010-03-31 2017-10-30 Gilead Pharmasset Llc Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
PT2596004E (pt) 2010-07-19 2014-11-28 Gilead Sciences Inc Métodos para a preparação de pró-fármacos de fosforamidato diastereomericamente puros
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
ES2671478T3 (es) * 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
JP2016506371A (ja) 2012-11-16 2016-03-03 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヌクレオシドプロドラッグを調製する方法
EP3013340B9 (en) 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
CZ307789B6 (cs) * 2014-04-15 2019-05-09 Zentiva, K.S. Způsob výroby biologicky účinných fosforamidátových léčiv
US10202411B2 (en) * 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
SI3160978T1 (sl) 2014-06-25 2020-11-30 NuCana plc Gemcitabin predzdravila
BR112016025787B1 (pt) 2014-06-25 2022-12-13 NuCana plc Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
ES2796089T3 (es) * 2014-08-25 2020-11-25 Medivir Ab Análogos de dioxano de uridina para el tratamiento de cáncer
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
WO2016098123A2 (en) 2014-12-16 2016-06-23 Laurus Labs Private Ltd A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
DK3197456T3 (en) 2015-05-14 2018-06-06 NuCana plc CANCER TREATMENTS
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN112156102B (zh) 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药(苏州)股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
AU2015411525B2 (en) 2015-10-05 2021-08-12 NuCana plc Combination therapy
WO2017087517A1 (en) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs
JP6889180B2 (ja) 2015-12-11 2021-06-18 ニューカナ パブリック リミテッド カンパニー ホスフェート誘導体及びゲムシタビンプロドラッグnuc−1031のジアステレオ選択性合成
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
PT3393478T (pt) 2015-12-23 2020-03-24 NuCana plc Terapia combinada
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens

Also Published As

Publication number Publication date
IL271159A (en) 2020-01-30
IL312228B1 (en) 2025-02-01
BR112019026747A2 (pt) 2020-06-30
US11897913B2 (en) 2024-02-13
IL312228B2 (en) 2025-06-01
AU2018284131A1 (en) 2020-01-16
IL312228A (en) 2024-06-01
PH12019502825A1 (en) 2020-10-26
AU2022204691B2 (en) 2023-11-23
CN110753697B (zh) 2023-10-13
KR20200016864A (ko) 2020-02-17
CN110753697A (zh) 2020-02-04
SA519410795B1 (ar) 2023-11-19
KR20240127483A (ko) 2024-08-22
MX2019014907A (es) 2020-02-13
JP7279991B2 (ja) 2023-05-23
IL302559A (en) 2023-07-01
CL2019003632A1 (es) 2020-08-14
IL302559B1 (en) 2024-05-01
IL271159B1 (en) 2023-06-01
MX2019014914A (es) 2020-02-13
MA49379A (fr) 2020-04-22
WO2018229493A2 (en) 2018-12-20
US11414452B2 (en) 2022-08-16
IL302559B2 (en) 2024-09-01
JP7248209B2 (ja) 2023-03-29
CN110785425B (zh) 2023-11-21
CA3065682A1 (en) 2018-12-20
JP2023095954A (ja) 2023-07-06
JP7525687B2 (ja) 2024-07-30
AU2024200428B2 (en) 2025-10-16
MX391332B (es) 2025-03-21
AU2024200428A1 (en) 2024-02-08
KR102695300B1 (ko) 2024-08-16
CN117486959A (zh) 2024-02-02
JP2020523381A (ja) 2020-08-06
EP3638685A1 (en) 2020-04-22
IL271159B2 (en) 2023-10-01
AU2018284131B2 (en) 2022-04-07
US20200181190A1 (en) 2020-06-11
CN110785425A (zh) 2020-02-11
JP2024138523A (ja) 2024-10-08
JP2020523378A (ja) 2020-08-06
CA3064177A1 (en) 2018-12-20
US20200181186A1 (en) 2020-06-11
AU2022204691A1 (en) 2022-08-04
EP3638684A2 (en) 2020-04-22
GB201709471D0 (en) 2017-07-26
US20250171487A1 (en) 2025-05-29
US20220402962A1 (en) 2022-12-22
EA201992873A1 (ru) 2020-05-19
WO2018229495A1 (en) 2018-12-20
MX390901B (es) 2025-03-21
US12054511B2 (en) 2024-08-06
MX2022003822A (es) 2022-05-25
WO2018229493A3 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
IL271159A (en) Synthesis of diastereomerically pure proteid phosphates
IL271939A (en) A method for making synthesis gas
SG10202111790YA (en) Synthesis of omecamtiv mecarbil
PL3261044T3 (pl) System do indywidualnego wytwarzania produktów do noszenia lub medycznych
PL3577125T3 (pl) Postacie krystaliczne alafenamidu tenofowiru
GB201517844D0 (en) Binaural synthesis
EP3500286A4 (en) N-CARBOXYANHYDRIDE-BASED ELAMIPRETIDE SCALE SYNTHESIS
HUE066451T2 (hu) Mezotrion szintézise
IL272857A (en) Cofanalisib formulations
IL248283B (en) A method for the synthesis of cloprabine
GB2544486C (en) Synthesis of Ammonia
PT3678644T (pt) Formulações de copanlisib
IL250846A0 (en) Synthesis of cyclocreatin and its analogs
HK40017914A (en) Synthesis of substantially diastereomerically pure phosphate protides
PL3713939T3 (pl) Ulepszony sposób syntezy konstruktu łącznik-lek vc-seco
EP3267795A4 (en) Synthesis of cyclocreatine and analogs thereof
GB201912028D0 (en) Binaural synthesis
GB201807468D0 (en) Methods of synthesis
HK40011646A (en) In vivo synthesis of sialylated compounds
GB201803484D0 (en) Improvements relating to the manufacture of inserts
HK40007680A (en) N-carboxyanhydride-based-scale synthesis of elamipretide
PT3320102T (pt) Processo para a síntese de pentostatina
GB201611620D0 (en) Novel formulations of valsartan
GB201402645D0 (en) Moisturising body lotion for the treatment of the visible symptoms of Keratosis Pilaris